Farxiga (Dapagliflozin) Manufacturing, Supply Chain & Shortage History

How AstraZeneca Manufactures Dapagliflozin

Dapagliflozin is a synthetic small molecule, not a biologic. That distinction matters for supply reliability. Small-molecule drugs follow well-established chemical synthesis pathways that can be scaled across multiple manufacturing sites more readily than biologic agents requiring living cell cultures.

The active pharmaceutical ingredient (API) is produced through a multi-step organic synthesis centered on forming a carbon-glycosidic (C-glucoside) bond. This bond links the glucose-derived sugar moiety to an aglycone pharmacophore, and it is the structural feature that makes SGLT2 inhibitors resistant to enzymatic degradation by glucosidases in the gut 1. Early synthetic routes published by Bristol-Myers Squibb (which co-developed dapagliflozin with AstraZeneca before BMS exited the partnership in 2014) involved a Friedel-Crafts glycosylation step, though AstraZeneca has since optimized the commercial-scale process for yield and purity 2.

AstraZeneca's manufacturing network spans facilities in Sweden, the United Kingdom, and contracted production sites in Asia. The company's 2024 annual report disclosed capital investments exceeding $2 billion in global manufacturing capacity expansion, driven in part by Farxiga's rapid revenue growth. Finished tablets are produced as immediate-release, film-coated formulations in 5 mg and 10 mg strengths, packaged under cGMP conditions and distributed through standard pharmaceutical cold-chain-exempt logistics, since dapagliflozin tablets are stable at room temperature 3.

Regulatory Approval Timeline and Indication Expansion

The FDA approved dapagliflozin in January 2014 for glycemic control in adults with type 2 diabetes. That initial approval was narrow. What followed was a deliberate, trial-driven expansion that changed Farxiga's market position and supply calculus entirely.

In May 2020, the FDA granted approval for heart failure with reduced ejection fraction (HFrEF), based on the DAPA-HF trial (N=4,744), which demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death compared with placebo (HR 0.74; 95% CI, 0.65 to 0.85; P<0.001) 4. Dr. John McMurray, the trial's principal investigator, stated: "Dapagliflozin reduced the risk of worsening heart failure and death from cardiovascular causes, regardless of the presence or absence of diabetes" 4.

In April 2021, the FDA approved dapagliflozin for chronic kidney disease (CKD) based on DAPA-CKD (N=4,304), which showed a 39% relative risk reduction in the composite of sustained decline in eGFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes (HR 0.61; 95% CI, 0.51 to 0.72; P<0.001) 5. That trial was stopped early for efficacy. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines now recommend SGLT2 inhibitors as first-line therapy for CKD patients with eGFR ≥20 mL/min/1.73 m², stating: "We recommend treating patients with CKD with an SGLT2 inhibitor" 6.

Each new indication added millions of potential patients to the prescribing pool, creating supply pressure that AstraZeneca had to anticipate and manage.

Supply Chain Architecture and Redundancy

AstraZeneca operates a hub-and-spoke supply model for Farxiga. API synthesis is concentrated at a limited number of qualified sites (primarily in Europe), while tableting, coating, and packaging occur at multiple secondary facilities including contract manufacturing organizations (CMOs).

This structure carries both strengths and vulnerabilities. Redundancy at the finished-dosage level means that a disruption at one packaging site can be offset by shifting volume to another. The bottleneck risk sits at the API stage. If an API facility experiences a regulatory hold, equipment failure, or raw-material shortage, downstream production stalls regardless of available tableting capacity.

AstraZeneca's 2023 sustainability report noted that the company maintains "strategic safety stock" for high-demand products, including Farxiga, typically representing 8 to 12 weeks of projected demand 7. The DECLARE-TIMI 58 cardiovascular outcomes trial (N=17,160) had already signaled broad prescribing interest before the HF and CKD indications were approved; in that trial, dapagliflozin met its primary safety endpoint and reduced the rate of cardiovascular death or hospitalization for heart failure by 17% (HR 0.83; 95% CI, 0.73 to 0.95; P=0.005) 8.

The revenue trajectory tells the supply story in numbers. Farxiga generated $1.5 billion in 2019, $3.3 billion in 2021, $5.9 billion in 2023, and approximately $7.1 billion in 2024, making it AstraZeneca's second-highest-revenue product globally. Scaling production to match that growth rate without interruption requires years of advance planning for API capacity, CMO contracting, and raw-material procurement.

FDA Shortage History

Dapagliflozin has not appeared on the FDA Drug Shortage Database as a sustained shortage. This distinguishes it from the widely publicized supply crises affecting GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which remained on the FDA shortage list for extended periods between 2022 and 2025 9.

Intermittent, localized supply tightness has occurred. Pharmacies in certain U.S. regions reported difficulty filling Farxiga prescriptions during late 2021 and early 2022, coinciding with the post-DAPA-CKD approval demand surge. AstraZeneca acknowledged "temporary distribution delays" in communications to wholesalers but did not trigger a formal FDA shortage notification, as supply was redistributed from other channels within days 9.

Several factors have protected Farxiga's supply relative to injectable biologics and peptides:

Small-molecule synthesis is inherently more scalable. Chemical synthesis can be replicated across qualified sites far more quickly than scaling up bioreactor-based peptide manufacturing.

Oral solid dosage is logistically simpler. Tablets do not require cold chain, specialized injection devices, or the fill-finish complexity of prefilled pens and syringes.

Demand growth, while steep, was more predictable. AstraZeneca began scaling Farxiga production during the DAPA-HF and DAPA-CKD trial enrollment phases, well before regulatory decisions. GLP-1 shortages, by contrast, were partly driven by off-label weight-loss prescribing that was difficult to forecast.

How Dapagliflozin Works: SGLT2 Inhibition

Dapagliflozin selectively inhibits the sodium-glucose co-transporter 2 (SGLT2) protein in the proximal convoluted tubule of the kidney. SGLT2 is responsible for reabsorbing approximately 90% of filtered glucose. By blocking this transporter, dapagliflozin causes the kidneys to excrete 60 to 80 grams of glucose per day in the urine, lowering blood glucose without depending on insulin secretion or sensitivity 10.

This mechanism produces effects beyond glycemia. The glycosuric action induces a mild osmotic diuresis and natriuresis, reducing plasma volume and preload. These hemodynamic changes are measurable within the first 48 hours of dosing and persist with chronic use. In DAPA-HF, the cardiovascular benefit was apparent within 28 days of randomization 4.

The renal protective effects involve tubuloglomerular feedback. By increasing sodium delivery to the macula densa, SGLT2 inhibition restores afferent arteriolar tone, reducing intraglomerular hyperfiltration pressure. This mechanism is distinct from renin-angiotensin-aldosterone system (RAAS) blockade and explains why the two drug classes provide additive renoprotection 5.

Dapagliflozin has an oral bioavailability of approximately 78%, reaches peak plasma concentration in 2 hours, and has a terminal half-life of approximately 12.9 hours, supporting once-daily dosing. It is metabolized primarily by UGT1A9 (a glucuronidation enzyme), which reduces the risk of cytochrome P450-mediated drug interactions 3.

Generic Competition and Future Supply Outlook

AstraZeneca holds composition-of-matter and formulation patents on dapagliflozin in the United States, with key patent expirations occurring between 2025 and 2027 depending on patent term extensions and pediatric exclusivity. Multiple abbreviated new drug application (ANDA) filings have been submitted to the FDA, and initial generic approvals are expected to follow patent resolution 11.

Generic entry will substantially alter the supply picture. Once two or more generic manufacturers are producing dapagliflozin, total U.S. manufacturing capacity will increase, unit costs will drop, and the risk of single-source supply disruption will decrease. India-based generic manufacturers including Sun Pharmaceutical and Dr. Reddy's Laboratories have published process chemistry for dapagliflozin API synthesis 12.

The clinical demand trajectory continues upward. The 2024 American Heart Association (AHA) and American College of Cardiology (ACC) heart failure guidelines recommend SGLT2 inhibitors as a pillar of guideline-directed medical therapy for heart failure across the ejection fraction spectrum (HFrEF, HFmrEF, and HFpEF) 13. The DELIVER trial (N=6,263) extended the evidence to HFpEF, showing dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 18% (HR 0.82; 95% CI, 0.73 to 0.92; P<0.001) 14.

Combined, the heart failure population alone (estimated at 6.7 million U.S. adults per AHA 2024 statistics) represents a prescribing base that will require sustained, high-volume SGLT2 inhibitor production for years 15.

What Patients Should Know About Farxiga Availability

If a pharmacy reports Farxiga as temporarily out of stock, the issue is almost always a local distribution problem rather than a national shortage. Patients can request that their pharmacist check wholesaler availability from a secondary distributor. AstraZeneca also maintains a patient assistance program (Farxiga Savings Card and AZ&Me program) that may assist with access and cost barriers 3.

Patients should not discontinue dapagliflozin abruptly without consulting their prescriber. While SGLT2 inhibitors do not carry the rebound risks associated with some cardiovascular medications (e.g., beta-blockers or clonidine), stopping therapy removes the ongoing cardiorenal protection that trials have demonstrated.

For prescribers managing supply uncertainty, therapeutic substitution within the SGLT2 inhibitor class (to empagliflozin, for example) is pharmacologically reasonable, though insurance formulary coverage and individual patient factors should guide the switch. The 2022 ADA Standards of Care note that cardiovascular and renal outcome benefits are considered a class effect for SGLT2 inhibitors with outcome trial data 16.

The current dapagliflozin 10 mg tablet supply remains stable across major U.S. wholesalers (McKesson, AmerisourceBergen, Cardinal Health) as of May 2026.